Stability of liposomes in circulation is markedly enhanced by structural modification of their phospholipid component

Bali, Anu; Dhawan, Sameer; Gupta, C. M.

doi:10.1016/0014-5793(83)80185-9

Cited by 18 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The head-group modifications include introduction of ligands,52–55 functional groups (such as malemide) for chemical conjugation of ligands (such as antibodies),56 and/or polymerizable moieties57 to produce stable liposomes. The carbonyl ester bonds of the glycerol backbone of PC (at both the sn-1 and sn-2 position) have been the choice for modifications with either ether58,59 or carbamyl esters,60–62 resulting in modulation of stability and in vivo circulation of these liposomes. The fatty acyl chain length and degree of unsaturation are important factors that govern bilayer packing properties of liposomes and contribute to the observed phase-transition (Tm) effect.…”

Section: Liposomes As Drug Carriersmentioning

confidence: 99%

Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic

Puri

Loomis

Smith

et al. 2009

Crit Rev Ther Drug Carrier Syst

859

559

View full text Add to dashboard Cite

In recent years, various nanotechnology platforms in the area of medical biology, including both diagnostics and therapy, have gained remarkable attention. Moreover, research and development of engineered multifunctional nanoparticles as pharmaceutical drug carriers have spurred exponential growth in applications to medicine in the last decade. Design principles of these nanoparticles, including nano-emulsions, dendrimers, nano-gold, liposomes, drug-carrier conjugates, antibody-drug complexes, and magnetic nanoparticles, are primarily based on unique assemblies of synthetic, natural, or biological components, including but not limited to synthetic polymers, metal ions, oils, and lipids as their building blocks. However, the potential success of these particles in the clinic relies on consideration of important parameters such as nanoparticle fabrication strategies, their physical properties, drug loading efficiencies, drug release potential, and, most importantly, minimum toxicity of the carrier itself. Among these, lipid-based nanoparticles bear the advantage of being the least toxic for in vivo applications, and significant progress has been made in the area of DNA/RNA and drug delivery using lipid-based nanoassemblies. In this review, we will primarily focus on the recent advances and updates on lipid-based nanoparticles for their projected applications in drug delivery. We begin with a review of current activities in the field of liposomes (the so-called honorary nanoparticles), and challenging issues of targeting and triggering will be discussed in detail. We will further describe nanoparticles derived from a novel class of amphipathic lipids called bolaamphiphiles with unique lipid assembly features that have been recently examined as drug/DNA delivery vehicles. Finally, an overview of an emerging novel class of particles (based on lipid components other than phospholipids), solid lipid nanoparticles and nanostructured lipid carriers will be presented. We conclude with a few examples of clinically successful formulations of currently available lipid-based nanoparticles.

show abstract

Section: Liposomes As Drug Carriersmentioning

confidence: 99%

Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic

Puri

Loomis

Smith

et al. 2009

Crit Rev Ther Drug Carrier Syst

859

559

View full text Add to dashboard Cite

show abstract

“…The tetrapeptides I and II were synthesized by conventional methods and characterized by FAB/CAD mass spectrometry (unpublished). 6-CF (Eastman-Kodak) was used after purification as in [ 131. The radioactivity and 6-CF were measured as in [14].…”

Section: Methodsmentioning

confidence: 99%

“…Only the liposomes found in the top 3/4 of the supernatant were used. Free and liposomal 6-CF were separated by gel filtration [14]. The outer diameter of the liposomes, as measured by electron microscopy, was about 35-55 nm (mean size, -40 nm), which remained unaffected upon incorporating I (or II) in the liposomes bilayer.…”

Section: Liposomesmentioning

confidence: 99%

Specific interactions of liposomes with PMN leukocytes upon incorporating tuftsin in their bilayers

et al. 1984

Self Cite

View full text Add to dashboard Cite

Incorporation of tuftsin derivatives, Thr‐Lys‐Pro‐Arg‐NH‐C18H37 or Thr‐Lys‐Pro‐Arg‐NH‐(CH2)2‐NH‐COC15H31, into an egg phosphatidylcholine/cholesterol liposome bilayer led to significantly enhanced binding of the liposomes to PMN leukocytes at 37°C but not at 0°C. Under identical conditions, no such enhanced binding of the liposomes was observed with erythrocytes and lymphocytes. These results demon‐strate that grafting of tuftsin on the liposome bilayer enables the liposome to recognize specifically the PMN leukocytes and to deliver its contents to these cells.

show abstract

“…It was observed more than 10 years ago that blood plasma contained factors that were able to drastically enhance the rate at which encapsulated solutes were released from liposomes (ZBOROWSKI et al 1977) and that mainly high density lipoproteins were responsible for these liposome destabilizing effects . Also, the exploitation of phospholipid analogues, such as ether phospholipids, was shown to have a beneficial effect on plasma stability of liposomes (GUPTA et al 1981;BALI et al 1983;HERMETTER and PALTAUF 1983;AGARWAL et al 1986a,b). Incorporation of high proportions of cholesterol, for example, was shown to reduce the plasma-induced leakage of encapsulated solutes quite substantially (KIRBY et al 1980a,b;GREGORIADlS, 1980, 1981), as was the use of phospholipids with relatively high gel to liquid crystalline phase transition temperatures (SENIOR and GREGORIADIS 1982a;SCHERPHOF et al 1979).…”

Section: B Interactions With Body Fluidsmentioning

confidence: 99%

Targeted Drug Delivery

Audus¹,

Juliano²

1991

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Stability of liposomes in circulation is markedly enhanced by structural modification of their phospholipid component

Abstract: Replacement of the C-2 ester group in phosphatidylcholine by the carbamyloxy function rendered its liposomes completely stable and longer living in the circulation of rats. Drug delivery Modified liposomes Blood clearance

Cited by 18 publications

References 17 publications

Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic

Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic

Specific interactions of liposomes with PMN leukocytes upon incorporating tuftsin in their bilayers

Targeted Drug Delivery

Contact Info

Product

Resources

About